PART I . Overview We are a biotechnology company committed to discovering and developing product candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair. Our current strategic focus is ophthalmology, where Wnt signaling plays a central role in retinal vascular integrity, barrier function, and tissue maintenance. We are located in South San Francisco, California. Our mission is to transform the treatment of serious ophthalmic disease by fully exploiting the Wnt pa...
Q2 FY2026 — expected 2026-08-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-23 | 2025-12-31 | 0001193125-26-119818 | EDGAR | 89K words |
| 2025-03-31 | 2024-12-31 | 0000950170-25-047712 | EDGAR | — |
| 2024-04-10 | 2023-12-31 | 0000950170-24-043399 | EDGAR | — |
| 2023-03-31 | 2022-12-31 | 0000950170-23-011118 | EDGAR | — |
| 2022-03-28 | 2021-12-31 | 0000950170-22-004787 | EDGAR | — |
| 2021-03-31 | 2020-12-31 | 0001104659-21-044518 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001193125-26-338120 | EDGAR | — |
| 2025-11-07 | 2025-09-30 | 0001193125-25-272422 | EDGAR | 62K words |
| 2025-08-08 | 2025-06-30 | 0000950170-25-105847 | EDGAR | — |
| 2025-05-09 | 2025-03-31 | 0000950170-25-068046 | EDGAR | — |
| 2024-11-06 | 2024-09-30 | 0000950170-24-122318 | EDGAR | — |
| 2024-08-12 | 2024-06-30 | 0000950170-24-095443 | EDGAR | — |
| 2024-05-08 | 2024-03-31 | 0000950170-24-055706 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0000950170-23-061150 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0000950170-23-040648 | EDGAR | — |
| 2023-05-10 | 2023-03-31 | 0000950170-23-020618 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0000950170-22-025096 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0000950170-22-016889 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-06 | 0001193125-26-338068 | EDGAR | — |
| 2026-03-23 | 0001193125-26-119757 | EDGAR | 3K words |
| 2026-01-30 | 0001193125-26-031798 | EDGAR | — |
| 2025-11-07 | 0001193125-25-272363 | EDGAR | — |
| 2025-10-17 | 0001193125-25-242518 | EDGAR | — |
| 2025-08-29 | 0000950170-25-112253 | EDGAR | — |
| 2025-08-08 | 0000950170-25-105839 | EDGAR | — |
| 2025-05-15 | 0000950170-25-072696 | EDGAR | — |
| 2025-05-09 | 0000950170-25-068011 | EDGAR | — |
| 2025-03-31 | 0000950170-25-047702 | EDGAR | — |
108 total filings indexed. 80 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001824893 |
| Ticker | SRZN |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.surrozen.com |
| Listed | 2021-08-12 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/SRZN (~200 tokens, structured JSON with cryptographic provenance)